Nicox (NICXF) Institutional Ownership: 3.81% (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NICXF Nicox SA NICXF
36 GF Score
Price $0.30
GF Value $0.60
! 2 Warning Signs
View Full Analysis

What is Nicox Institutional Ownership?

Nicox NICXF 36 Institutional Ownership is 3.81% as of Aug. 01, 2026. GuruFocus rates NICXF with a GF Score™ of 36/100 and a GF Value™ of $0.60. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nicox's institutional ownership is 3.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nicox's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nicox's Float Percentage Of Total Shares Outstanding is 0.00%.

Nicox Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Nicox's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nicox Institutional Ownership Chart

Nicox Historical Data

The historical data trend for Nicox can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 2.68 2.68 2.68 2.10 1.79 1.79 1.79 1.79 1.79 2.10
NICXF
36GF Score
Nicox SA NICXF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nicox Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.81% mean?
Nicox (NICXF) has a Institutional Ownership of 3.81% as of Aug. 01, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Nicox and its competitors.
Is Nicox's Institutional Ownership too high?
Nicox's current Institutional Ownership is 3.81%. Overall, Nicox has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Nicox's Institutional Ownership compare to VRTX and REGN?
Nicox's Institutional Ownership of 3.81% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Nicox and its competitors. Nicox's current Institutional Ownership is 3.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nicox stock overvalued right now?
Nicox (NICXF) has a current Institutional Ownership of 3.81%. The stock's GF Value™ is $0.60, compared to a current price of $0.30 — trading 50% below its estimated fair value. The current Institutional Ownership is 3.81%. Nicox's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Nicox (NICXF), the current Institutional Ownership is 3.81% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nicox (NICXF) Overvalued in 2026?

Based on GuruFocus' analysis, Nicox stock appears to be undervalued. The current stock price of $0.30 is trading 50% below its estimated GF Value™ of $0.60.

Key valuation signals for NICXF:

  • Institutional Ownership: 3.81%
  • GF Value™: $0.60 vs. price of $0.30 (50% below fair value)
  • GF Score™: 36/100 with 2 warning signs

No single metric tells the full story. See the NICXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nicox Business Description

Address Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
36GF Score

Get the complete analysis for NICXF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price
$0.60
GF Value